Why the study?
The study was conducted to investigate whether there is a link between type 2 diabetes complications and endothelin-1 overexpression.
Is there a significant difference in endothelin-1 gene expression among patients with hypertensive type 2 diabetes (with or without cardiovascular disease) compared to controls?
Observational (n=90)
Is there a significant difference in endothelin-1 gene expression among patients with hypertensive type 2 diabetes (with or without cardiovascular disease) compared to controls?
p-value: p=<0.05
Endothelin-1 gene expression is significantly altered in hypertensive patients with type 2 diabetes and cardiovascular disease, highlighting its potential as a biomarker or therapeutic target for early CVD.
The goal of this study is to see if there's a link between diabetes type 2 problems and endothelin-1 overexpression (ET-1). Where (90) blood samples from participants were obtained and divided into three groups: a first group representing individuals with (Hypertensive DMT2) and a second group representing (Hypertensive DMT2with CVD,), while the third group was represented by a control group. mRNA was extracted from blood samples then converted to cDNA by using the (qPCR) technique. When comparing the levels of ET-1 in the (hypertensive DMT2 and hypertensive DMT2with CVD groups ) to the control group, the results showed a significant difference (p<0.05), The current study analyzed the ET-1 gene in type 2 diabetes and cardiovascular disease, which could be a new target for early CVD therapy in the future.
No takes yet. Share an insight, caveat, or question.
Kadhim et al. (2022) conducted an observational in Type 2 Diabetes and Cardiovascular Disease (n=90). Hypertensive type 2 diabetes with or without cardiovascular disease vs. Control group was evaluated on Endothelin-1 (ET-1) gene expression (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: